The Supreme Court held a hearing on Monday to consider whether drugmakers can settle patent lawsuits with generic-drug makers by making arrangements to block generics. The court seemed conflicted after an hour of oral arguments, with some justices worrying that the practice would delay cheaper drugs coming to the market and hurt competition, while the court also noted that sometimes the arrangements are valid. The Federal Trade Commission has been fighting the practice for more than 10 years and contributed a brief to the Supreme Court challenge. Drugmakers are defending such deals to avert patent litigation.
Supreme Court holds hearing on patent settlement agreements
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||